Total Payments
$257,612
2024 Payments
$13,664
Companies
64
Transactions
465
Medicare Patients
6,244
Medicare Billing
$2.8M
Payment Breakdown by Category
Consulting$102,599 (39.8%)
Research$73,872 (28.7%)
Other$43,747 (17.0%)
Travel$24,348 (9.5%)
Food & Beverage$12,823 (5.0%)
Education$223.04 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $102,599 | 64 | 39.8% |
| Unspecified | $73,872 | 22 | 28.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,191 | 21 | 11.7% |
| Travel and Lodging | $24,348 | 46 | 9.5% |
| Honoraria | $13,486 | 11 | 5.2% |
| Food and Beverage | $12,823 | 286 | 5.0% |
| Education | $223.04 | 14 | 0.1% |
| Entertainment | $69.87 | 1 | 0.0% |
Payments by Type
General
$183,740
443 transactions
Research
$73,872
17 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $63,411 | 6 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $29,244 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $26,554 | 50 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $21,546 | 28 | $0 (2024) |
| F. Hoffmann-La Roche AG | $13,120 | 16 | $0 (2020) |
| Kite Pharma, Inc. | $12,804 | 14 | $0 (2022) |
| Genentech, Inc. | $12,011 | 4 | $0 (2019) |
| Cornerstone Specialty Network LLC | $9,468 | 15 | $0 (2024) |
| PFIZER INC. | $7,373 | 22 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $6,987 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,664 | 49 | AstraZeneca Pharmaceuticals LP ($3,283) |
| 2023 | $21,189 | 54 | Cornerstone Specialty Network LLC ($8,268) |
| 2022 | $20,681 | 60 | Kite Pharma, Inc. ($5,320) |
| 2021 | $27,852 | 56 | Kite Pharma, Inc. ($6,134) |
| 2020 | $31,219 | 46 | AstraZeneca Pharmaceuticals LP ($5,600) |
| 2019 | $64,070 | 80 | Eli Lilly and Company ($27,617) |
| 2018 | $43,548 | 40 | Eli Lilly and Company ($33,110) |
| 2017 | $35,389 | 80 | Millennium Pharmaceuticals, Inc. ($6,987) |
All Payment Transactions
465 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: Oncology | ||||||
| 12/23/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 12/12/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $149.31 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $1.81 | General |
| Category: Cardiovascular | ||||||
| 11/15/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $244.75 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.83 | General |
| Category: Rare Disease | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Oncology | ||||||
| 10/17/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $36.97 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.93 | General |
| Category: Oncology | ||||||
| 10/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $132.30 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,648.00 | General |
| 09/12/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $117.58 | General |
| Category: Oncology | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $277.50 | General |
| Category: Oncology | ||||||
| 09/02/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 07/23/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $988.00 | General |
| 07/02/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Oncology | ||||||
| 07/01/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 06/27/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER | Eli Lilly and Company | $60,590 | 2 |
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| Gazyva GA101 Plus Benda CLL | F. Hoffmann-La Roche AG | $3,909 | 2 |
| PROTOCOL FOR CONTINUED PATIENT ACCESS TO STUDY DRUG | Eli Lilly and Company | $2,368 | 2 |
| An Open-Label Study of Obinutuzumab GA101 Plus Bendamustine in Patients with Previously Untreated Chronic Lymphocytic Leukemia | F. Hoffmann-La Roche AG | $1,082 | 1 |
| NEJM EMERALD manuscript | Radius Health, Inc. | $858.63 | 2 |
| SABCS EMERALD presentation | Radius Health, Inc. | $464.82 | 2 |
| MONARCHER-A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIANS CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $315.70 | 1 |
| SABCS EMERALD abstract | Radius Health, Inc. | $166.68 | 2 |
| RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN | Eli Lilly and Company | $137.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 1,372 | 47,640 | $1.9M | $698,000 |
| 2022 | 36 | 1,346 | 51,554 | $1.2M | $448,684 |
| 2021 | 49 | 1,822 | 57,807 | $2.0M | $769,754 |
| 2020 | 44 | 1,704 | 47,946 | $2.3M | $866,980 |
Total Patients
6,244
Total Services
204,947
Medicare Billing
$2.8M
Procedure Codes
166
All Medicare Procedures & Services
166 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 7,200 | $792,000 | $311,852 | 39.4% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 15 | 4,570 | $388,450 | $153,374 | 39.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 53 | 61 | $188,800 | $69,228 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 256 | 508 | $123,914 | $46,572 | 37.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 2,100 | $94,080 | $37,947 | 40.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 76 | 156 | $49,935 | $14,856 | 29.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 40 | 26,010 | $52,020 | $10,146 | 19.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 57 | 66 | $57,750 | $8,437 | 14.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 96 | 167 | $21,042 | $7,762 | 36.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 23 | 29 | $26,665 | $5,558 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 37 | $12,691 | $5,030 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 67 | 80 | $13,760 | $4,831 | 35.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 61 | 239 | $11,327 | $2,676 | 23.6% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 27 | 34 | $18,785 | $2,320 | 12.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 45 | $7,210 | $2,142 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,056 | $2,022 | 40.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 37 | $6,295 | $1,990 | 31.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 36 | 103 | $4,635 | $1,543 | 33.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $4,125 | $1,457 | 35.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 58 | 136 | $4,770 | $1,411 | 29.6% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 16 | 16 | $7,775 | $1,131 | 14.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 49 | $3,185 | $1,060 | 33.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 49 | $4,410 | $1,009 | 22.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 12 | 22 | $2,332 | $858.11 | 36.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 19 | 22 | $2,200 | $535.04 | 24.3% |
About Dr. Sunil Babu, M.D
Dr. Sunil Babu, M.D is a Hematology & Oncology healthcare provider based in Fort Wayne, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1891968301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sunil Babu, M.D has received a total of $257,612 in payments from pharmaceutical and medical device companies, with $13,664 received in 2024. These payments were reported across 465 transactions from 64 companies. The most common payment nature is "Consulting Fee" ($102,599).
As a Medicare-enrolled provider, Babu has provided services to 6,244 Medicare beneficiaries, totaling 204,947 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 166 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Fort Wayne, IN
- Active Since 04/04/2008
- Last Updated 05/15/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1891968301
Products in Payments
- SOLIRIS (Drug) $14,436
- Yescarta (Drug) $12,750
- Non-Covered Product (Drug) $12,357
- IMFINZI (Drug) $8,178
- GAZYVA (Biological) $7,796
- TALZENNA (Drug) $7,140
- ALUNBRIG (Drug) $6,731
- Ultomiris (Drug) $5,540
- OPDIVO (Biological) $5,040
- Gazyva (Biological) $4,991
- CALQUENCE (Drug) $4,465
- IMBRUVICA (Drug) $4,129
- Revlimid (Drug) $3,733
- VARUBI (Drug) $3,261
- Monoferric (Drug) $2,422
- ULTOMIRIS (Biological) $2,382
- FOTIVDA (Drug) $2,271
- LONSURF (Drug) $2,100
- JEVTANA (Drug) $1,997
- ABECMA (Biological) $1,976
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Wayne
Dolly Quispe Leveau, M.d, M.D
Hematology & Oncology — Payments: $73,162
Hematology & Oncology $73,162
Jeffrey Letzer, Do, DO
Hematology & Oncology — Payments: $43,943
Hematology & Oncology $43,943
Dr. Robert Manges, Md, MD
Hematology & Oncology — Payments: $42,660
Hematology & Oncology $42,660
Farrukh Adhami, Md, MD
Hematology & Oncology — Payments: $35,244
Hematology & Oncology $35,244
Dr. Murugavel Muthusamy, M.d, M.D
Hematology & Oncology — Payments: $23,326
Hematology & Oncology $23,326
Melanie Clark
Hematology & Oncology — Payments: $15,035
Hematology & Oncology $15,035